Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge

Abstract Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing o...

Full description

Bibliographic Details
Published in:Tropical Medicine and Health
Main Authors: Qudus Olajide Lawal, Joseph Okoeguale, Sebastine Oseghae Oiwoh, ThankGod Akhigbe, Reuben Agbons Eifediyi, Sylvanus Akhalufo Okogbenin
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2024
Subjects:
Ribavirin
Lassa fever
Antiviral therapy
Dose formulation
Ampoule
Arctic medicine. Tropical medicine
RC955-962
Arctic
Online Access:https://doi.org/10.1186/s41182-024-00609-0
https://doaj.org/article/59eff9db5ae74e70b7ea7134042a8695
Description
Summary:Abstract Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease.

Similar Items